90
Participants
Start Date
April 19, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2029
Cobimetinib
Cobimetinib will be administered at a maximal dose of 60 mg daily for patients \<18 years old and a flat dose of 40 mg daily for patients ≥18 years for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Children's National Hospital, Washington D.C.
RECRUITING
John Hopkins University School of Medicine, Baltimore
NOT_YET_RECRUITING
NACHO Consortium, Memphis
TERMINATED
University of Wisconsin-American Family Children's Hospital, Madison
RECRUITING
Arkansas Children's Hospital, Little Rock
RECRUITING
Children's Medical Center- UTSW, Dallas
RECRUITING
Texas Children's Hospital, Houston
RECRUITING
Phoenix Children's Hospital, Phoenix
RECRUITING
Children's Hospital of Orange County, Orange
RECRUITING
UCSF Benioff Children's Hospital, San Francisco
RECRUITING
Dana Farber Cancer Institute, Boston Children's, Boston
Collaborators (1)
Baylor College of Medicine
OTHER
North American Consortium for Histiocytosis
OTHER
Genentech, Inc.
INDUSTRY
Carl Allen
OTHER